OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Other Current Liabilities

Last Annual Value

2.35M

3-Year CAGR

13%

5-Year CAGR

-69%

10-Year CAGR

-44%

OT

OS Therapies Incorporated Competitors Analysis of Other Current Liabilities

OSTX · NYSE
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.35M
-20.7%7.8%N/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
919.08K
-6.2%69.4%6.8%
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
2.61M
38.2%36.7%N/A
13.53M
26.6%15.4%N/A
7.63M
58.5%188.3%52.9%
1.43M
39.4%64.3%N/A
33.64M
110.1%190.4%N/A
8.83M
-7.8%N/AN/A
161.05K
-33.8%N/AN/A
23.99M
75.7%37.5%N/A
45755.71B
29164.0%2665.6%440.1%
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42